<DOC>
	<DOC>NCT01241214</DOC>
	<brief_summary>This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.</brief_summary>
	<brief_title>Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>Males and females aged 18 to 70 years. Clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last two years. Adequate exposure to mountain cedar pollen. Positive skin prick test to mountain cedar allergen within 12 months of screening. Sufficient nasal symptom score during a runin period. Nonallergic rhinitis. Bacterial or viral respiratory tract infection. Chronic respiratory disorders. Asthma requiring treatment other than inhaled shortacting Beta2agonists. Ocular infections or surgery, nasal obstruction, nasal biopsy or surgery, sinus surgery or perforation. Smoking within the last year. Ongoing or recent treatment for seasonal allergic rhinitis. Initiation of allergen immunotherapy within 6 months of screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Seasonal allergic rhinitis</keyword>
	<keyword>SAR</keyword>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Allergies</keyword>
</DOC>